Skip to main content
Download PDF

Identification and interaction analysis of key genes and microRNAs in hepatocellular carcinoma by bioinformatics analysis

World Journal of Surgical Oncology volume 15, Article number: 63 (2017) Cite this article

Abstract

Background

Hepatocellular carcinoma (HCC) is the most common liver malignancy worldwide. However, present studies of its multiple gene interaction and cellular pathways still could not explain the initiation and development of HCC perfectly. To find the key genes and miRNAs as well as their potential molecular mechanisms in HCC, microarray data GSE22058, GSE25097, and GSE57958 were analyzed.

Methods

The microarray datasets GSE22058, GSE25097, and GSE57958, including mRNA and miRNA profiles, were downloaded from the GEO database and were analyzed using GEO2R. Functional and pathway enrichment analyses were performed using the DAVID database, and the protein–protein interaction (PPI) network was constructed using the Cytoscape software. Finally, miRDB was applied to predict the targets of the differentially expressed miRNAs (DEMs).

Results

A total of 115 differentially expressed genes (DEGs) were found in HCC, including 52 up-regulated genes and 63 down-regulated genes. The gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses from DAVID showed that up-regulated genes were significantly enriched in chromosome segregation and cell division, while the down-regulated genes were mainly involved in complement activation, protein activation cascades, carboxylic acid metabolic processes, oxoacid metabolic processes, and the immune response. From the PPI network, the 18 nodes with the highest degree were screened as hub genes. Among them, ESR1 was found to have close interactions with FOXO1, CXCL12, and GNAO1. In addition, a total of 64 DEMs were identified, which included 58 up-regulated miRNAs and 6 down-regulated miRNAs. ESR1 was potentially targeted by five miRNAs, including hsa-mir-18a and hsa-mir-221.

Conclusions

The roles of DEMs like hsa-mir-221 in HCC through interactions with DEGs such as ESR1 and CXCL12 may provide new clues for the diagnosis and treatment of HCC patients.

Background

HCC is the most common primary liver malignancy and is one of the leading causes of cancer-related deaths around the world. In Asia, there are more than 580,000 new cases expected every year [1]. As well as other carcinomas, gene aberrations, cellular context, and environmental influences are believed to be the reason of the occurrence, progression, and metastasis of HCC. Although the study of the multiple genes and cellular pathways that take part in the initiation and development of HCC has been discussed for many years, the therapy for HCC accurately still remains scarcely. Accordingly, it is crucial to investigate the molecular mechanisms involved in the proliferation, apoptosis, and invasion of HCC for the improvement of diagnostic and therapeutic strategies.

In recent years, the microarray, a high-throughput platform for analysis of gene expression, has been extensively conducted as an efficient tool for the identification of general genetic alteration during tumorigenesis [2]. While studies of DEGs and DEMs of HCC have been performed in the past decades and some of their functions in different pathways, biological processes, or molecular functions have been reported, there remain questions about how the DEGs and microRNAs interact through molecular pathways because of limitations on the comparative analysis of the DEGs in independent studies. Currently, due to bioinformatics methods, we can finally deal with the data generated by microarray technology and find the interactions among DEGs and microRNAs, especially the pathways in the interaction network, to conclude their potential mechanisms in HCC.

In this study, we chose three gene expression profiles (GSE22058, GSE25097, and GSE57958), which were downloaded from the GEO database (https://www.ncbi.nlm.nih.gov/geo/), to obtain DEGs and DEMs between liver cancer tissues and normal tissue samples. Then, functional enrichment and network analyses were applied to identify the DEGs, which were combined with mRNA–microRNA interaction analysis, to describe the key genes and miRNAs as well as their potential molecular mechanisms in HCC.

Methods

Collection and inclusion criteria of studies

We searched the GEO database (https://www.ncbi.nlm.nih.gov/geo/) for publicly available studies from January 1, 2010 to October 30, 2016 using the following keywords: “hepatocellular carcinoma” (study keyword), “Homo sapiens” (organism), “Expression profiling by array” (study type), “70 to 3000” (sample count) and “tissue” (attribute name). After a systematic review, 13 GSE studies were retrieved. The inclusion criteria for studies were as follows: (1) samples diagnosed with HCC tissue samples and normal tissue samples, (2) gene expression profiling of mRNA, (3) sample count of each group are more than 35, and (4) sufficient information to perform the analysis. Then, three gene expression profiles (GSE22058, GSE25097, and GSE57958) were collected for analysis.

Microarray data

Three gene expression profiles (GSE22058, GSE25097, and GSE57958) were downloaded from the GEO database. The array data for GSE25097 included 268 HCC tissue samples and 243 normal tissue samples [3]. The array data for GSE57958 consisted of 39 HCC tissue samples and 39 normal tissue samples [4]. The array data for GSE22058 consisted of one mRNA expression profile (including 100 HCC tissue samples and 97 normal tissue samples) and a miRNA expression profile (including 96 HCC tissue samples and 96 normal tissue samples) [5].

Data processing

GEO2R (http://www.ncbi.nlm.nih.gov/geo/geo2r/) is an interactive web tool for comparing two groups of data that can analyze any GEO series [6]. GEO2R was applied to screen differentially expressed mRNAs and miRNAs between HCC and normal tissue samples. The adjusted P values (adj. P) using Benjamini and Hochberg (BH) false discovery rate (FDR) method by default were applied to correct for the occurrence of false positive results. An adj. P < 0.05 and a |logFC| ≥ 1 were set as the cut-off criteria. Heat map of DEGs was generated using the online tool Morpheus (https://software.broadinstitute.org/morpheus/).

Functional and pathway enrichment analysis

Gene ontology (GO) is a common method for annotating genes, gene products and sequences to underlying biological phenomena [7, 8]; the Kyoto Encyclopedia of Genes and Genomes (KEGG) is an integrated database resource for biological interpretation of genome sequences and other high-throughput data [9]. Both analyses were available in the DAVID database (https://david.ncifcrf.gov/), which is a bioinformatics data resource composed of an integrated biology knowledge base and analysis tools to extract meaningful biological information from large quantities of genes and protein collections [10]. GO and KEGG analyses were performed using the DAVID database to identify DEGs. A P value <0.05 was set as the cut-off criterion.

PPI network construction and analysis of modules

The STRING database (http://string-db.org/) is an online software that aims to provide a critical assessment and integration of protein–protein interactions, including direct (physical) and indirect (functional) associations [11]. Cytoscape is a popular open-source software tool for the visual exploration of biomolecule interaction networks composed of protein, gene, and other types of interactions [12]. The DEGs were mapped to STRING to evaluate the PPI information and then visualized with Cytoscape. A combined score >0.15 was set as the cut-off criterion. To screen the hub genes, node degree ≥10 was set as the cut-off criterion. Then, the Molecular Complex Detection (MCODE) plug-in was used to screen modules of hub genes from the PPI network with degree cut-off = 10, haircut on, node score cut-off = 0.2, k-core = 2, and max. depth = 100. Moreover, the functional and pathway enrichment analyses of DEGs in each module were performed by DAVID. A P value <0.05 was set as the cut-off criterion.

Prediction of miRNA targets

The target genes of the DEMs from GSE22058 were predicted with miRDB (http://mirdb.org/miRDB/), which is an online database for predicting microRNA targets [13]. The target genes were aligned with the DEGs to obtain an intersection for further analysis.

Results

Identification of DEGs

A total of 2021, 1097, and 409 DEGs were identified after the analyses of the GSE22058, GSE25097, and GSE57958 datasets, respectively (Additional files 1, 2, and 3). Among them, 116 genes were found in all three datasets (Fig. 1). Of these, 115 gene expressions were matched, including 52 up-regulated genes and 63 down-regulated genes in HCC tissue samples compared with normal liver tissue samples.

Fig. 1
figure 1

Identification of differentially expressed genes (DEGs) in mRNA expression profiling datasets GSE22058, GSE25097, and GSE57958

Full size image

Functional and pathway enrichment analyses

To further understand the function and mechanism of the identified DEGs, functional and pathway enrichment analyses, including GO and KEGG, were performed using DAVID. The GO term enrichment analysis showed that in the biological processes-associated category, the up-regulated genes were significantly enriched in chromosome segregation and cell division, while the down-regulated genes were mainly involved in complement activation, protein activation cascades, carboxylic acid metabolic processes, oxoacid metabolic processes, and the immune response (Table 1). In addition, cell component analysis showed that the up-regulated genes were enriched in the chromosome, cytosol, proteinaceous extracellular matrix, and basement membrane collagen trimer, and that the down-regulated genes were mainly found in the collagen trimer, blood microparticles, membrane attack complexes, membrane-bounded vesicles, and the extracellular region part (Table 1). Moreover, for molecular function, the up-regulated genes were enriched in histone deacetylase binding, and the down-regulated genes were enriched in steroid binding, aromatase activity, oxidoreductase activity, monooxygenase activity, and serine-type endopeptidase activity (Table 1). Furthermore, the KEGG pathway analysis showed that the up-regulated genes were significantly enriched in ECM-receptor interaction, while four pathways were overrepresented in the down-regulated genes: chemical carcinogenesis, steroid hormone biosynthesis, retinol metabolism, and drug metabolism—cytochrome P450 (Table 1).

Table 1 Functional and pathway enrichment analysis of up-regulated and down-regulated genes in hepatocellular carcinoma (HCC) tissue
Full size table

PPI network construction and analysis of modules

Ninety-seven nodes and 319 edges were mapped in the PPI network of identified DEGs, including 43 up-regulated genes and 54 down-regulated genes (Fig. 2a). The 18 nodes with the higher degrees were screened as hub genes, including TOP2A, FOS, TK1, CDC20, ESR1, CCNB2, CXCL12, FOXO1, HMMR, VWF, ACSM3, COL4A1, ZIC2, RFC4, TXNRD1, GNAO1, CYP3A4, and RAP2A (Table 2). Hub genes expression heat map in GSE25097 is shown in Fig. 2c. Among these, ESR1 was found to have close interactions with FOS, FOXO1, CXCL12, and GNAO1; CDC20 had interactions with CCNB2, CDCA5, CENPM, and GMNN (combined score > 0.90). A significant module including 16 nodes and 58 edges was obtained using MCODE (Fig. 2b). GO term enrichment analysis showed that in biological processes, the genes in this module were mainly associated with the cell cycle and responses to oxidation reactions and steroid hormones (Table 3). The genes were significantly enriched in the nucleoplasm, cytosol, and chromosome by cell component analysis (Table 3). The molecular function analysis showed that the genes were mainly involved in the binding of macromolecular complexes, chromatin, enzymes, RNA polymerases, and carbohydrate derivatives (Table 3). The KEGG analysis showed that the genes were mainly enriched in ECM-receptor interactions (Table 3).

Fig. 2
figure 2

Protein–protein interaction (PPI) network and hub genes. a PPI network of differentially expressed genes (DEGs). b A significant module selected from the PPI network. Red nodes denote up-regulated genes, while green nodes denote down-regulated genes. Black border shows that the gene is a potential target for differentially expressed miRNAs (DEMs). The lines represent an interaction relationship between the nodes. c Hub genes expression heat map (11 up-regulated genes and 7 down-regulated genes) in GSE25097. Red: up-regulation; purple: down-regulation

Full size image
Table 2 Hub genes and their related DEMs
Full size table
Table 3 Functional and pathway enrichment analysis of the genes in the module
Full size table

miRNA-DEG pairs

A total number of 64 DEMs between HCC tissue samples and normal tissue samples were identified after the analyses of the GSE22058 datasets (Additional file 4), including 58 up-regulated miRNAs and 6 down-regulated miRNAs (Fig. 3). The miRDB database was used to predict target genes of the identified DEMs (Table 4). By comparing the target gene to the DEGs, we screened the genes with a consistent expression trend for further analysis. miRNA-221, one of the most significantly up-regulated miRNAs, was found to target ESR1, FOS, and CXCL12. In addition, miRNA-142-5p, one of the main down-regulated miRNAs, potentially targeted ANKRD29, IGF2BP3, and IGSF3. Moreover, we found that ESR1 was potentially targeted by five miRNAs, including hsa-mir-148b, hsa-mir-181b, hsa-mir-18a, hsa-mir-19a, and hsa-mir-221 (Table 2). In addition, FOXO1 was the potential target of hsa-mir-135b, hsa-mir-324, and hsa-mir-369.

Fig. 3
figure 3

Heat map of the differentially expressed miRNAs (DEMs) (58 up-regulated genes and 6 down-regulated genes). Red: up-regulation; purple: down-regulation

Full size image
Table 4 DEMs in HCC tissue and their potential target genes
Full size table

Discussion

Although people have continuously studied HCC, the early diagnosis and treatment of HCC is still a large problem due to the lack of understanding of the molecular mechanisms that drive the occurrence and development of HCC. Therefore, in-depth research into the factors and mechanisms of HCC progression are necessary for HCC diagnosis and treatment. Due to well-developed microarray technology, it is easier to determine the general genetic alterations in the progression of diseases, which can allow for the identification of gene targets for diagnosis, therapy, and prognosis of tumors.

In our study, a total of 115 DEGs were screened, including 52 up-regulated genes and 63 down-regulated genes. The up-regulated genes were enriched in chromosome segregation and cell division, while the down-regulated genes were mainly involved in complement activation, protein activation cascades, carboxylic acid metabolic processes, oxoacid metabolic processes, and the immune response. Moreover, by constructing the PPI, we identified high degree genes including ESR1, which was found to have close interactions with FOXO1, FOS, CXCL12, and GNAO1.

ESR1 could encode the transcription factor that enhances the response to various stimuli such as estrogen and growth factors in different kinds of tissue types [14]. Some researchers noticed that it may play a potential tumor suppressor features in HCC with its novel associations among the hepatocyte-specific pathways [15]. Moreover, there are also some reports claiming that ESR1 could suppress the inflammatory process mediated by interleukin-6 and reduce hepatic injury and the compensatory proliferation of hepatocytes [16]. Recent research has shown that cancers such as non-small cell lung cancer (NSCLC) also have very low-expression level of ESR1 [17]. FOXO, which has four members including FOXO1, is one of the 19 kinds of forkhead box transcription factors and is mainly express in mammals [18, 19]. Reports showed that the overexpression of FOXO could inhibit the growth and size of tumors [18, 20]. Some research on breast cancer also claimed that when FOXO proteins accumulate in the nucleus, they could suspend cell cycle progression and promote apoptosis [20, 21]. Recent research on FOXO proteins provides a new viewpoint that they may possess antitumor properties in HCC, inducing the expression of pro-apoptotic genes and interfering with signaling cascades, such as the Wnt/β-catenin, PI3K/AKT/mTOR, or MAPK pathways that are commonly changed in HCC [21, 22]. Meanwhile, FOS is reported as an oncogene in several kinds of cancers such as bladder cancer and HCC [23, 24]. There is also a recent research that shows that FOS has a high expression in HCC cell lines [25]. Yet in this work, we found it as a low-expression hub gene through the Microarray data analysis. Therefore it may need a further test in the future experiments and is excluded from the work this time. However, the molecular mechanism of ESR1 for HCC and the relationship of ESR1 and FOXO1 were rarely explored. In our study, we found that ESR1 and FOXO1 both had low-expression levels and had an interaction, indicating a joint function in HCC.

Stromal-derived factor 1 alpha, also known as CXCL12, is a specific ligand for CXCR4 and CXCR7. These three proteins together drive the migration of progenitor cells in embryonic development. Some invasion-related or metastasis-related pathways, such as cytokine-cytokine receptor interaction and axon guidance, contain CXCL12 as an important role in the regulation of themselves [26]. Several studies have shown that CXCL12 has a lower expression level in HCC tissue than in normal liver tissue [27]. There is also a study showing that CXCL12 and CXR4 may play significant roles in the metastasis of HCC by promoting the migration of tumor cells [28]. GNAO1 is a member of the subunit family of Gα proteins. As a molecular switch that controls signal transduction, the deregulation of GNAO1 can facilitate oncogenesis [29]. Kan et al. found that the role of mutant GNAO1 in oncogenesis might be to act as a tumor suppressor gene [30]. Jia et al. combined an integrated CNA (chromosomal copy number alteration) analysis with gene expression data to demonstrate that GNAO1 may play a key role in the pathogenesis of HCC [31]. Meanwhile, some research has shown that GNAO1 also plays a significant role in breast cancer and hepatocellular carcinoma [32]. Above all, these results suggest that ESR1, FOXO1, CXCL12, and GNAO1 are involved in the pathogenesis of carcinoma by affecting cell division, complement activation, and protein activation cascades, which support our findings.

Increasing evidence has shown that the dysregulation of miRNAs is an important part of the pathogenesis of multiple cancer types, including HCC. In our study, we identified 64 DEMs, including 58 up-regulated and 6 down-regulated miRNAs in HCC. miR-221 is one of the most significantly up-regulated miRNAs and was found to target ESR1, FOS, and CXCL12. Additionally, miRNA-142-5p is the main down-regulated miRNA and potentially targets ANKRD29, IGF2BP3, and IGSF3. A recent report shows that miRNA-142-5p could regulate the expression of IGF2BP3, which is strongly associated with an advanced tumor stage and is a predictor of poor prognosis among patients with HCC, as with IGF2BP1 [33]. miR-221, which is one of the most frequently and consistently up-regulated microRNAs (miRNAs) in human cancer, has been suggested to act as a tumor promoter. A recent study presents that miR-221 overexpression could accelerate hepatocyte proliferation and contribute to liver tumorigenesis [34]. Additionally, miR-221 also had a higher expression level in NSCLC [35]. Further researches give a conclusion that through the stimulation from staphylococcal nuclease domain-containing 1 (SND1), miR-221 could result in the overexpression of angiogenic factors like angiogenin and CXCL16 [36]. By using parallel measurement, a change in CDKN1B, CDKN1C, paralemmin-2, and CXCL12 levels was suggested as consistent with increased miR-221 activity in the same group. Meanwhile, Yau et al. found that miR-221 and miR-18a levels were also significantly higher in colorectal carcinoma tissues compared with their respective adjacent normal tissues [37]. miR-18a and miR-19a, regulated by E2F-MYC signaling pathways, are reported playing a crucial role in inducing cell proliferation [38]. As we found that ESR1 was potentially targeted by hsa-mir-148b, hsa-mir-181b, hsa-mir-18a, hsa-mir-19a, and hsa-mir-221, it indicates that these miRNAs may play a key role in HCC by mediating ESR1.

Conclusions

In conclusion, our study tried to identify DEGs using comprehensive bioinformatics analyses and found potential biomarkers to predict the progression of diseases. After analysis, a total of 115 DEGs and 64 DEMs were screened including ESR1, FOXO1, CXCL12, GNAO1, and several miRNAs such as miR-221 and miR-142-5p. Significantly, the roles of hsa-mir-148b, hsa-mir-181b, hsa-mir-18a, hsa-mir-19a, and hsa-mir-221 in HCC through interactions with ESR1 and CXCL12 may provide new clues for the diagnosis and treatment of HCC patients. However, lacking of experimental verification is a limitation of this study. In the future, these predicted results obtained from bioinformatics analysis can be verified by further experimental researches, such as qRT-PCR and Western Blot.

Abbreviations

adj. P :

Adjusted P values

BH:

Benjamini and Hochberg

DEGs:

Differentially expressed genes

DEMs:

Differentially expressed miRNAs

FDR:

False discovery rate

GO:

Gene ontology

HCC:

Hepatocellular carcinoma

KEGG:

Kyoto Encyclopedia of Genes and Genomes

PPI:

Protein–protein interaction

References

  1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.

    Article  PubMed  Google Scholar 

  2. Andreozzi M, Quintavalle C, Benz D, Quagliata L, Matter M, Calabrese D, Tosti N, Ruiz C, Trapani F, Tornillo L, et al. HMGA1 expression in human hepatocellular carcinoma correlates with poor prognosis and promotes tumor growth and migration in in vitro models. Neoplasia. 2016;18:724–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Tung EK, Mak CK, Fatima S, Lo RC, Zhao H, Zhang C, Dai H, Poon RT, Yuen MF, Lai CL, et al. Clinicopathological and prognostic significance of serum and tissue Dickkopf-1 levels in human hepatocellular carcinoma. Liver Int. 2011;31:1494–504.

    Article  CAS  PubMed  Google Scholar 

  4. Mah WC, Thurnherr T, Chow PK, Chung AY, Ooi LL, Toh HC, Teh BT, Saunthararajah Y, Lee CG. Methylation profiles reveal distinct subgroup of hepatocellular carcinoma patients with poor prognosis. PLoS One. 2014;9:e104158.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Burchard J, Zhang C, Liu AM, Poon RT, Lee NP, Wong KF, Sham PC, Lam BY, Ferguson MD, Tokiwa G, et al. microRNA-122 as a regulator of mitochondrial metabolic gene network in hepatocellular carcinoma. Mol Syst Biol. 2010;6:402.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH, Sherman PM, Holko M, et al. NCBI GEO: archive for functional genomics data sets—update. Nucleic Acids Res. 2013;41:D991–5.

    Article  CAS  PubMed  Google Scholar 

  7. Bastos HP, Tavares B, Pesquita C, Faria D, Couto FM. Application of gene ontology to gene identification. Methods Mol Biol. 2011;760:141–57.

    Article  CAS  PubMed  Google Scholar 

  8. Gene Ontology C. The Gene Ontology (GO) project in 2006. Nucleic Acids Res. 2006;34:D322–6.

    Article  Google Scholar 

  9. Kanehisa M, Sato Y, Kawashima M, Furumichi M, Tanabe M. KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res. 2016;44:D457–62.

    Article  PubMed  Google Scholar 

  10. da Huang W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4:44–57.

    Article  CAS  Google Scholar 

  11. Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, Simonovic M, Roth A, Santos A, Tsafou KP, et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2015;43:D447–52.

    Article  PubMed  Google Scholar 

  12. Su G, Morris JH, Demchak B, Bader GD. Biological network exploration with Cytoscape 3. Curr Protoc Bioinformatics. 2014;47:8 13 11–24.

    Google Scholar 

  13. Wong N, Wang X. miRDB: an online resource for microRNA target prediction and functional annotations. Nucleic Acids Res. 2015;43:D146–52.

    Article  PubMed  Google Scholar 

  14. Magnani L, Lupien M. Chromatin and epigenetic determinants of estrogen receptor alpha (ESR1) signaling. Mol Cell Endocrinol. 2014;382:633–41.

    Article  CAS  PubMed  Google Scholar 

  15. Ramesh V, Ganesan K. Integrative functional genomic delineation of the cascades of transcriptional changes involved in hepatocellular carcinoma progression. Int J Cancer. 2016;139:1586–97.

    Article  CAS  PubMed  Google Scholar 

  16. Baldissera VD, Alves AF, Almeida S, Porawski M, Giovenardi M. Hepatocellular carcinoma and estrogen receptors: polymorphisms and isoforms relations and implications. Med Hypotheses. 2016;86:67–70.

    Article  CAS  PubMed  Google Scholar 

  17. Li W, Tse LA, Wang F. Prognostic value of estrogen receptors mRNA expression in non-small cell lung cancer: a systematic review and meta-analysis. Steroids. 2015;104:129–36.

    Article  CAS  PubMed  Google Scholar 

  18. Yu W, Wang J, Ma L, Tang X, Qiao Y, Pan Q, Yu Y, Sun F. CD166 plays a pro-carcinogenic role in liver cancer cells via inhibition of FOXO proteins through AKT. Oncol Rep. 2014;32:677–83.

    PubMed  Google Scholar 

  19. Zhang X, Tang N, Hadden TJ, Rishi AK. Akt, FoxO and regulation of apoptosis. Biochim Biophys Acta. 1813;2011:1978–86.

    Google Scholar 

  20. Medema RH, Kops GJ, Bos JL, Burgering BM. AFX-like forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature. 2000;404:782–7.

    Article  CAS  PubMed  Google Scholar 

  21. Zhang X, Wang Y, Wang J, Sun F. Protein-protein interactions among signaling pathways may become new therapeutic targets in liver cancer (review). Oncol Rep. 2016;35:625–38.

    CAS  PubMed  Google Scholar 

  22. Carbajo-Pescador S, Mauriz JL, Garcia-Palomo A, Gonzalez-Gallego J. FoxO proteins: regulation and molecular targets in liver cancer. Curr Med Chem. 2014;21:1231–46.

    Article  CAS  PubMed  Google Scholar 

  23. Li X, Zhang X, Xie W, Zhou C, Li Y, Zhang X. Alterations in transcription and protein expressions of HCC-related genes in HepG2 cells caused by microcystin-LR. Toxicol In Vitro. 2017;40:115–23.

    Article  CAS  PubMed  Google Scholar 

  24. Li S, Xu X, Xu X, Hu Z, Wu J, Zhu Y, Chen H, Mao Y, Lin Y, Luo J, et al. MicroRNA-490-5p inhibits proliferation of bladder cancer by targeting c-Fos. Biochem Biophys Res Commun. 2013;441:976–81.

    Article  CAS  PubMed  Google Scholar 

  25. Wang Y, Jiang T, Li Z, Lu L, Zhang R, Zhang D, Wang X, Tan J. Analysis of differentially co-expressed genes based on microarray data of hepatocellular carcinoma. Neoplasma. 2017;64:216–21.

  26. Ding M, Li J, Yu Y, Liu H, Yan Z, Wang J, Qian Q. Integrated analysis of miRNA, gene, and pathway regulatory networks in hepatic cancer stem cells. J Transl Med. 2015;13:259.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Ghanem I, Riveiro ME, Paradis V, Faivre S, de Parga PM, Raymond E. Insights on the CXCL12-CXCR4 axis in hepatocellular carcinoma carcinogenesis. Am J Transl Res. 2014;6:340–52.

    PubMed  PubMed Central  Google Scholar 

  28. Liu H, Pan Z, Li A, Fu S, Lei Y, Sun H, Wu M, Zhou W. Roles of chemokine receptor 4 (CXCR4) and chemokine ligand 12 (CXCL12) in metastasis of hepatocellular carcinoma cells. Cell Mol Immunol. 2008;5:373–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Pei X, Zhang J, Wu L, Lu B, Zhang X, Yang D, Liu J. The down-regulation of GNAO1 and its promoting role in hepatocellular carcinoma. Biosci Rep. 2013;33:755–60.

  30. Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, Stern HM, Yue P, Haverty PM, Bourgon R, Zheng J, et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature. 2010;466:869–73.

    Article  CAS  PubMed  Google Scholar 

  31. Jia D, Wei L, Guo W, Zha R, Bao M, Chen Z, Zhao Y, Ge C, Zhao F, Chen T, et al. Genome-wide copy number analyses identified novel cancer genes in hepatocellular carcinoma. Hepatology. 2011;54:1227–36.

    Article  CAS  PubMed  Google Scholar 

  32. Liu Z, Zhang J, Wu L, Liu J, Zhang M. Overexpression of GNAO1 correlates with poor prognosis in patients with gastric cancer and plays a role in gastric cancer cell proliferation and apoptosis. Int J Mol Med. 2014;33:589–96.

    CAS  PubMed  Google Scholar 

  33. Liu X, Sempere LF, Galimberti F, Freemantle SJ, Black C, Dragnev KH, Ma Y, Fiering S, Memoli V, Li H, et al. Uncovering growth-suppressive MicroRNAs in lung cancer. Clin Cancer Res. 2009;15:1177–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Yuan Q, Loya K, Rani B, Mobus S, Balakrishnan A, Lamle J, Cathomen T, Vogel A, Manns MP, Ott M, et al. MicroRNA-221 overexpression accelerates hepatocyte proliferation during liver regeneration. Hepatology. 2013;57:299–310.

    Article  CAS  PubMed  Google Scholar 

  35. Duncavage E, Goodgame B, Sezhiyan A, Govindan R, Pfeifer J. Use of microRNA expression levels to predict outcomes in resected stage I non-small cell lung cancer. J Thorac Oncol. 2010;5:1755–63.

    Article  PubMed  Google Scholar 

  36. Bronte F, Bronte G, Fanale D, Caruso S, Bronte E, Bavetta MG, Fiorentino E, Rolfo C, Bazan V, Di Marco V, Russo A. HepatomiRNoma: the proposal of a new network of targets for diagnosis, prognosis and therapy in hepatocellular carcinoma. Crit Rev Oncol Hematol. 2016;97:312–21.

    Article  PubMed  Google Scholar 

  37. Yau TO, Wu CW, Dong Y, Tang CM, Ng SS, Chan FK, Sung JJ, Yu J. microRNA-221 and microRNA-18a identification in stool as potential biomarkers for the non-invasive diagnosis of colorectal carcinoma. Br J Cancer. 2014;111:1765–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Ramesh V, Ganesan K. Integrative analysis of transcriptome and miRNome unveils the key regulatory connections involved in different stages of hepatocellular carcinoma. Genes Cells. 2016;21:949–65.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

This study was funded by grants from the National Natural Science Foundation of China (No. 81672959), the Natural Science Foundation of Chongqing, China (No. cstc2015shmszx120019), and the Graduate Student Research Innovation Project of Chongqing, China (No. CYS15127).

Availability of data and materials

The datasets supporting the conclusions of this article are included within the article.

Authors’ contributions

TM and DZ participated in the design of this study, and they both performed the statistical analysis and drafted the manuscript. TTL, ZG, and JLP carried out the study and collected important background information and data. XFW, DFZ, and ZJW helped to draft the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Not applicable.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author information

Author notes

    Authors and Affiliations

    1. Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, People’s Republic of China

      Tong Mou, Di Zhu, Xufu Wei, Tingting Li, Daofeng Zheng, Junliang Pu, Zhen Guo & Zhongjun Wu

    Authors
    1. Tong Mou
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Di Zhu
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Xufu Wei
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Tingting Li
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Daofeng Zheng
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Junliang Pu
      View author publications

      You can also search for this author in PubMed Google Scholar

    7. Zhen Guo
      View author publications

      You can also search for this author in PubMed Google Scholar

    8. Zhongjun Wu
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Zhongjun Wu.

    Additional files

    Additional file 1:

    Complete list of differentially expressed genes (DEGs) in GSE22058. (DOCX 183 kb)

    Additional file 2:

    Complete list of differentially expressed genes (DEGs) in GSE25097. (DOCX 103 kb)

    Additional file 3:

    Complete list of differentially expressed genes (DEGs) in GSE57958. (DOCX 50 kb)

    Additional file 4:

    Complete list of differentially expressed miRNAs (DEMs) in GSE22058. (DOCX 19 kb)

    Rights and permissions

    Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Mou, T., Zhu, D., Wei, X. et al. Identification and interaction analysis of key genes and microRNAs in hepatocellular carcinoma by bioinformatics analysis. World J Surg Onc 15, 63 (2017). https://doi.org/10.1186/s12957-017-1127-2

    Download citation

    • Received:

    • Accepted:

    • Published:

    • DOI: https://doi.org/10.1186/s12957-017-1127-2

    Keywords

    World Journal of Surgical Oncology

    ISSN: 1477-7819

    Contact us